Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion type Assertion NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_head.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion description "[A variety of immune cell therapies proposed for use in the treatment of cancer, including both autologous cells (Lymphokine Activated Killer, Cytokine Induced Killer) or cell lines (TALL-104, NK-92), rely on recognition of NKG2D ligands on malignant cells for targeting.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_provenance.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion evidence source_evidence_literature NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_provenance.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion SIO_000772 21389869 NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_provenance.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion wasDerivedFrom befree-20140225 NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_provenance.
- NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_assertion wasGeneratedBy ECO_0000203 NP331301.RAmXyugoDQ0fNa0fWmrrWU5EEMeUUN3X1DFF5aMIvo-7s130_provenance.